aTYR PHARMA INC
Therapeutic molecules derived from tRNA synthetase biology
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Latest Form D
- $45.8M, Sep 2017
- Total capital
- $122M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $122M
- 2 Form D · last Sep 2017
- 109 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 24
- 16 pending · first 2014
- Rank in peer group#71 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$45.8M
- Private capital raisedForm D · SEC · 1st filing$76.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#71 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- John D. MendleinResearcherExecutive Officer, DirectorLinked by 1 patent
- Akkaraju C. SrinivasDirectorNamed in SEC Form D filings
- Amir C. NashatDirectorNamed in SEC Form D filings
- Amir H. Nashat, Sc.D.DirectorNamed in SEC Form D filings
- David C. WeinerExecutive OfficerNamed in SEC Form D filings
- Ed C. PenhoetDirectorNamed in SEC Form D filings
Show all 19 people
- Frederic C. ChereauExecutive OfficerNamed in SEC Form D filings
- James C. BlairDirectorNamed in SEC Form D filings
- Jeffrey S. HatfieldDirectorNamed in SEC Form D filings
- John T. BlakeExecutive OfficerNamed in SEC Form D filings
- John K. ClarkeDirectorNamed in SEC Form D filings
- Kathryn C. FalbergDirectorNamed in SEC Form D filings
- Mark P. GoldbergDirectorNamed in SEC Form D filings
- Nancy D. KruegerExecutive OfficerNamed in SEC Form D filings
- Paul C. SchimmelDirectorNamed in SEC Form D filings
- Sanjay S. ShuklaExecutive OfficerNamed in SEC Form D filings
- Sanuj K. RavindranExecutive OfficerNamed in SEC Form D filings
- Srini S. AkkarajuDirectorNamed in SEC Form D filings
- Timothy P. CoughlinDirectorNamed in SEC Form D filings
What it has protected
USPTO · 24 granted of 40- PendingCompositions And Methods Comprising ANTI-NRP2 AntibodiesUSPTOApplication 19293892
- GrantedHistidyl-trna Synthetase-fc Conjugates And Therapeutics Using The SameUSPTOUS 12,492,392
- GrantedCompositions Comprising ANTI-NRP2 AntibodiesUSPTOUS 12,410,253
Show all 40 patent records
- Compositions And Methods Comprising ANTI-NRP2 AntibodiesApr 2, 2026 · Application 19293892Pending
- Histidyl-trna Synthetase-fc Conjugates And Therapeutics Using The SameDec 9, 2025 · US 12,492,392Granted
- Compositions Comprising ANTI-NRP2 AntibodiesSep 9, 2025 · US 12,410,253Granted
- Compositions And Methods Comprising ANTI-NRP2 AntibodiesJul 3, 2025 · Application 18875942Pending
- COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2b ANTIBODIESJun 12, 2025 · Application 18840865Pending
- Antibodies Which Bind To The B2 Or C Domain Of Human NRP2Mar 6, 2025 · Application 18765952Pending
- COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIESDec 19, 2024 · Application 18703912Pending
- Compositions And Methods Comprising ANTI-NRP2 AntibodiesAug 20, 2024 · US 12,065,495Granted
- Therapeutic Compositions Comprising ANTI-NRP2 AntibodiesNov 7, 2023 · US 11,807,687Granted
- Compositions And Methods For Treating Lung InflammationSep 26, 2023 · US 11,767,520Granted
- Compositions And Methods For Treating NRP2-ASSOCIATED DiseasesFeb 9, 2023 · Application 17841187Pending
- Compositions And Methods Comprising ANTI-NRP2 AntibodiesNov 22, 2022 · US 11,505,610Granted
- Histidyl-trna Synthetase-fc ConjugatesJul 27, 2021 · US 11,072,787Granted
- Histidyl-trna Synthetase-fc ConjugatesJul 14, 2020 · US 10,711,260Granted
- Compositions And Methods For Treating NRP2-ASSOCIATED DiseasesMar 19, 2020 · Application 16523783Pending
- Histidyl-trna Synthetase-fc ConjugatesNov 12, 2019 · US 10,472,618Granted
- Histidyl-trna Synthetase-fc ConjugatesOct 9, 2018 · US 10,093,915Granted
- Anti-hrs Antibodies And Combinaton Therapies For Treating CancersOct 4, 2018 · Application 15828170Pending
- Aminoacyl Trna Synthetases For Modulating InflammationApr 17, 2018 · US 9,943,577Granted
- Compositions And Methods Comprising Aspartyl-trna Synthetases Having Non-canonical Biological ActivitiesFeb 20, 2018 · US 9,896,680Granted
- Pegylated Aspartyl-trna Synthetase PolypeptidesNov 21, 2017 · US 9,822,353Granted
- Aspartyl-trna SynthetasesNov 14, 2017 · US 9,816,084Granted
- Compositions And Methods Comprising Glycyl-trna Synthetases Having Non-canonical Biological ActivitiesOct 19, 2017 · Application 15415328Pending
- Thrombopoietic Activity Of Tyrosyl-trna Synthetase PolypeptidesJul 27, 2017 · Application 15289555Pending
- Aspartyl-trna Synthetase-fc ConjugatesJun 27, 2017 · US 9,688,978Granted
- Polypeptide Structural Motifs Associated With Cell Signaling ActivityApr 6, 2017 · Application 15239399Pending
- Histidyl-trna Synthetase-fc ConjugatesMar 7, 2017 · US 9,587,235Granted
- Compositions And Methods Comprising Glycyl-trna Synthetases Having Non-canonical Biological ActivitiesMar 7, 2017 · US 9,585,946Granted
- Innovative Discovery Of Therapeutic, Diagnostic, And Antibody Compositions Related To Protein Fragments Of P38 Multi-trna Synthetase ComplexFeb 23, 2017 · Application 15195772Pending
- Aminoacyl Trna Synthetases For Modulating InflammationJan 10, 2017 · US 9,540,628Granted
- Thrombopoietic Activity Of Tyrosyl-trna Synthetase PolypeptidesNov 22, 2016 · US 9,499,810Granted
- Polypeptide Structural Motifs Associated With Cell Signaling ActivitySep 27, 2016 · US 9,453,214Granted
- Innovative Discovery Of Therapeutic, Diagnostic, And Antibody Compositions Related To Protein Fragments Of P38 Multi-trna Synthetase ComplexAug 2, 2016 · US 9,404,104Granted
- Amino Acyl Trna Synthetases For Modulating InflammationMay 3, 2016 · US 9,328,340Granted
- Compositions And Methods Comprising Glycyl-trna Synthetases Having Non-canonical Biological ActivitiesOct 13, 2015 · US 9,157,076Granted
- Compositions And Methods Comprising Glycyl-trna Synthetases Having Non-canonical Biological ActivitiesJun 10, 2014 · US 8,747,840Granted
- Structures Of Human Histidyl-trna Synthetase And Methods Of UseMar 6, 2014 · Application 13948982Pending
- Polypeptide Structural Motifs Associated With Cell Signaling ActivityApplication PCTUS2010025642Pending
- Compositions And Methods Comprising Glycyl-trna Synthetases Having Non-canonical Biological ActivitiesApplication PCTUS2009048915Pending
- Thrombopoietic Activity Of Tyrosyl-trna Synthetase PolypeptidesApplication PCTUS2009046910Pending
Related companies, and why
- FIVE ELEVEN PHARMA, INC.Similar federal contract value in Biotech · null in contracts
- Z BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
- Antios Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Liberation Bioindustries, Inc.Similar federal contract value in Biotech · null in contracts
- EDITAS MEDICINE, INC.Similar federal contract value in Biotech · null in contracts
- ChromaDex Corp.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .